Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Approves Glaxosmithkline Plc's Breo Ellipta To Treat Lung Disease Jointly Developed With Theravance Inc-DJ


Friday, 10 May 2013 11:46am EDT 

Dow Jones reported that the U.S. Food and Drug Administration approved a new drug that will be marketed by GlaxoSmithKline PLC to treat chronic obstructive pulmonary disease, or COPD. The drug, Breo Ellipta, is administered once-daily with an inhaler. The FDA's approval was expected after a federal advisory panel endorsed the product last month. Breo was developed by Theravance Inc. and GlaxoSmithKline. It has the potential to be a successor to Glaxo's Advair, which should be taken twice daily. Breo Ellipta combines the corticosteroid fluticasone with vilanterol, a new active ingredient. The FDA said the product isn't approved to treat asthma. 

Company Quote

50.08
0.04 +0.08%
24 Jul 2014